Family Medicine · Kew Gardens, NY
NPI
1235210956
Since 2006
Specialty
Family Medicine
Code 207Q00000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
11909 Metropolitan Ave
Kew Gardens, NY, 11415
Phone (718) 850-1414
Groups this clinician bills Medicare through
Medicare paid, 2024
$249K
3,888 services
Medicare patients, 2024
286
Average age 77
Drug cost, 2024
$4.1M
16,158 prescriptions
Company payments, 2025
$1,557
From 15 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Inna Kigel was code 99213 (office e&m - established), 2,038 times for 257 patients. In total Inna Kigel billed 3,888 services in 18 codes, and Medicare paid $249K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-04-03.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 2,038 | 257 | $70.22 | $143K |
| 99442 Telephone Services | Office | 1,013 | 204 | $69.87 | $71K |
| 36415 Venipuncture Blood Collection | Office | 361 | 181 | $8.63 | $3,117 |
| 99349 Home E&M - New and Established | Office | 132 | 46 | $91.75 | $12K |
| G0180 Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 105 | 59 | $45.55 | $4,783 |
| G0179 Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | Office | 71 | 61 | $33.19 | $2,356 |
| G0008 Administration of influenza virus vaccine | Office | 48 | 48 | $36.42 | $1,748 |
| 90662 Vaccine Product | Office | 45 | 45 | $81.82 | $3,682 |
| 99214 Office E&M - Established | Office | 23 | 22 | $93.75 | $2,156 |
| 99212 Office E&M - Established | Office | 15 | 15 | $48.27 | $724 |
| 99496 Chronic, Principal, and Transitional Care Management | Office | 14 | 13 | $220.32 | $3,084 |
By year: 2022 $144K for 2,278 services; 2023 $246K for 3,470 services; 2024 $249K for 3,888 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 361 | 181 | $8.63 | $3,117 |
Medicare prescription drug claims, 2024
In 2024, the drug Inna Kigel prescribed most often to Medicare patients was Linzess (Linaclotide), with 457 prescriptions and refills. In total Inna Kigel wrote 16,158 Medicare prescriptions that cost $4.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Linzess Linaclotide | 457 | 544 | 60 | $274K |
| Rosuvastatin Calcium Generic | 406 | 589 | 88 | $2,371 |
| Amlodipine Besylate Generic | 379 | 573 | 74 | $1,038 |
| Azithromycin Generic | 333 | 333 | 175 | $1,223 |
| Diclofenac Sodium Generic | 329 | 336 | 68 | $173K |
| Vascepa Icosapent Ethyl | 275 | 314 | 53 | $104K |
| Janumet Sitagliptin Phos/Metformin Hcl | 272 | 320 | 36 | $164K |
| Zenpep Lipase/Protease/Amylase | 269 | 300 | 51 | $362K |
| Metoprolol Tartrate Generic | 267 | 437 | 54 | $1,011 |
| Clonidine Hcl Generic | 263 | 365 | 76 | $1,303 |
| Fluticasone Propionate Generic | 259 | 323 | 80 | $3,383 |
| Myrbetriq Mirabegron | 237 | 304 | 39 | $131K |
| Creon Lipase/Protease/Amylase | 219 | 255 | 68 | $190K |
| Losartan Potassium Generic | 203 | 353 | 38 | $1,126 |
| Atorvastatin Calcium Generic | 195 | 370 | 51 | $968 |
Brand drugs: 5,614 claims; generic drugs: 10,288 claims; opioid claims: 158.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Inna Kigel $1,557 ($1,557 in general payments such as food, travel and fees) from 15 companies. The largest payer was GlaxoSmithKline, LLC. with $250.
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. GSK | 18 | $250 |
| AstraZeneca Pharmaceuticals LP AZN | 10 | $233 |
| Abbvie Inc. ABBV | 11 | $227 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 9 | $198 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 12 | $195 |
| Novo Nordisk Inc NVO | 5 | $126 |
| Gilead Sciences, Inc. GILD | 4 | $81.07 |
| Sumitomo Pharma America, Inc. 4506.T | 2 | $47.6 |
| Lilly USA, LLC LLY | 2 | $42.53 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 2 | $41.02 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.